444 related articles for article (PubMed ID: 32592278)
21. [Reults of treatment with protocols BFM 90 and BFM 95].
Sakić M; Berbić-Fazlagić J
Med Arh; 2006; 60(6):369-72. PubMed ID: 17297851
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.
Pang L; Liang Y; Pan J; Wang JR; Chai YH; Zhao WL
Pediatr Hematol Oncol; 2015 Apr; 32(3):173-81. PubMed ID: 25551271
[TBL] [Abstract][Full Text] [Related]
23. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
24. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
Sun XF; Jiang WQ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Li YH; Zhou ZM; Zhen ZJ; Xia Y; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1687-91. PubMed ID: 15601561
[TBL] [Abstract][Full Text] [Related]
26. [Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma].
Sun XF; Zhen ZJ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Zhou ZM; Li YH; Xia Y; Ling JY; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):58-61. PubMed ID: 17575697
[TBL] [Abstract][Full Text] [Related]
27. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
28. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch.
Novakova M; Zaliova M; Fiser K; Vakrmanova B; Slamova L; Musilova A; Brüggemann M; Ritgen M; Fronkova E; Kalina T; Stary J; Winkowska L; Svec P; Kolenova A; Stuchly J; Zuna J; Trka J; Hrusak O; Mejstrikova E
Haematologica; 2021 Aug; 106(8):2066-2075. PubMed ID: 32646889
[TBL] [Abstract][Full Text] [Related]
29. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
[TBL] [Abstract][Full Text] [Related]
30. The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.
Paganin M; Grillo MF; Silvestri D; Scapinello G; Buldini B; Cazzaniga G; Biondi A; Valsecchi MG; Conter V; Te Kronnie G; Basso G
Br J Haematol; 2018 Sep; 182(5):705-711. PubMed ID: 29938780
[TBL] [Abstract][Full Text] [Related]
31. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Koehler R; Bartram CR
Klin Padiatr; 2013 May; 225 Suppl 1():S40-4. PubMed ID: 23700054
[TBL] [Abstract][Full Text] [Related]
32. Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87.
Campbell M; Salgado C; Quintana J; Becker A; Vargas L; Cabrera ME; Beresi V; Rojas J; Paez E; Tapia S; Zolezzi P; Advis P
Med Pediatr Oncol; 1999 Aug; 33(2):88-94. PubMed ID: 10398182
[TBL] [Abstract][Full Text] [Related]
33. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D
Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558
[TBL] [Abstract][Full Text] [Related]
34. [Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
Zhen ZJ; Xia Y; Ling JY; Tong GL; Lin L; Cai Y; Sun XF
Ai Zheng; 2009 Jul; 28(7):718-24. PubMed ID: 19624898
[TBL] [Abstract][Full Text] [Related]
35. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
[TBL] [Abstract][Full Text] [Related]
36. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group.
Bisio V; Zampini M; Tregnago C; Manara E; Salsi V; Di Meglio A; Masetti R; Togni M; Di Giacomo D; Minuzzo S; Leszl A; Zappavigna V; Rondelli R; Mecucci C; Pession A; Locatelli F; Basso G; Pigazzi M
Leukemia; 2017 Apr; 31(4):974-977. PubMed ID: 27890935
[No Abstract] [Full Text] [Related]
37. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M
Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312
[No Abstract] [Full Text] [Related]
38. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120.
Fazio G; Bresolin S; Silvestri D; Quadri M; Saitta C; Vendramini E; Buldini B; Palmi C; Bardini M; Grioni A; Rigamonti S; Galbiati M; Mecca S; Savino AM; Peloso A; Tu JW; Bhatia S; Borkhardt A; Micalizzi C; Lo Nigro L; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Te Kronnie G; Biondi A; Cazzaniga G
EBioMedicine; 2022 Sep; 83():104224. PubMed ID: 35985167
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
Glodkowska E; Bialas A; Jackowska T
Med Wieku Rozwoj; 2007; 11(2 Pt 1):153-8. PubMed ID: 17625285
[TBL] [Abstract][Full Text] [Related]
40. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group.
Borkhardt A; Cazzaniga G; Viehmann S; Valsecchi MG; Ludwig WD; Burci L; Mangioni S; Schrappe M; Riehm H; Lampert F; Basso G; Masera G; Harbott J; Biondi A
Blood; 1997 Jul; 90(2):571-7. PubMed ID: 9226156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
